CencoraMIL:1COR 55 EBITDA Margin % is 3.20% as of Mar. 2026, which is 176% above its 10-year median of 1.16. GuruFocus rates MIL:1COR with a GF Score™ of 55/100 and a GF Value™ of €233.91 (Fairly Valued). The stock has 1 warning sign investors should review. Among 119 Medical Distribution companies, Cencora ranks worse than 79.83% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cencora's EBITDA for the
three
months ended in Mar. 2026 was €2,168 Mil. Cencora's Revenue for the
three
months ended in Mar. 2026 was €67,778 Mil. Therefore, Cencora's EBITDA margin for the quarter that ended in Mar. 2026 was 3.20%.
Cencora (MIL:1COR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cencora EBITDA Margin % Related Terms
Cencora EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cencora's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1COR vs CAH, MCK, HSIC: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Cencora's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cencora EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cencora's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cencora's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cencora (MIL:1COR) has a EBITDA Margin % of 3.20% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cencora and its competitors. This is 176% above median its historical median of 1.16. According to the industry distribution chart, Cencora ranks #95 out of 119 companies in the Medical Distribution industry, placing it in the top 79.8%.
Is Cencora's EBITDA Margin % too high?
Cencora's current EBITDA Margin % of 3.20% is 176% above median its 10-year median of 1.16. The Medical Distribution industry median EBITDA Margin % is 4.31. Cencora's value of 3.20% is 25.8% below this industry median. Based on the distribution chart, Cencora ranks #95 out of 119 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cencora has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's EBITDA Margin % compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #95 out of 119 companies for EBITDA Margin %. This places Cencora in the lower half of its industry. The industry median EBITDA Margin % is 4.31. Cencora's value of 3.20% is 25.8% below this benchmark. While the company's 10-year median is 1.16 vs. the industry median of 4.31, Cencora has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cencora's current EBITDA Margin % of 3.20% is 25.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cencora and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cencora's current EBITDA Margin % is 3.20%, which is 176% above median its own 10-year median of 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (MIL:1COR) is currently considered Fairly Valued. The stock's GF Value™ is €233.91, compared to a current price of €229.90 — trading 1.7% below its estimated fair value. The current EBITDA Margin % is 3.20%, which is 176% above median its 10-year median of 1.16 and 25.8% below the Medical Distribution industry median of 4.31. Cencora's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cencora (MIL:1COR), the current EBITDA Margin % is 3.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (MIL:1COR) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be undervalued.
The current stock price of €229.90 is trading 1.7% below its estimated GF Value™ of €233.91.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for MIL:1COR:
EBITDA Margin %: 3.20% (176% above median its 10-year median of 1.16)
GF Value™: €233.91 vs. price of €229.90 (1.7% below fair value)
Industry Position: 25.8% below the Medical Distribution median (#95 of 119)
No single metric tells the full story. See the MIL:1COR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
55GF Score
Get the complete analysis for MIL:1COR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1COR has been successfully added to your 
